Senti Biosciences, Inc. - Common Stock (SNTI)

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Senti Biopharma shares rallied in premarket trading on Tuesday after its cancer treatment received a positive designation from the U.S. FDA.

As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Senti Bio missed Q3 2025 earnings and revenue estimates, but eyes a key catalyst with upcoming Phase 1 AML data at the ASH meeting.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Let's have a look at the stocks with an unusual volume in today's session.

U.S. stock futures were in negative territory during Tuesday’s premarket hours as the dollar slipped to 106.3 level.